Condition: Lung Cancers · Pancreatic Cancer · Neuroendocrine Tumors · Sponsor: Nanjing First Hospital, Nanjing Medical University
Evaluate the safety of the novel FAP targeted molecular probe 18F-FAPI-YQ104 labeled with radioactive isotopes in clinical applications and verify its effectiveness in tumor diagnosis.
This description comes directly from the study's public registry record.
Feng Wang · +8602552271491 · fengwangcn@hotmail.com
Always discuss trial participation with your own doctor first.
| Nanjing First Hospital | Nanjing, Jiangsu, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06937112